NanoViricides Announces $2 Million Direct Offering

NanoViricides, Inc., a clinical stage company known for its antiviral innovations, declared the pricing of a registered direct offering. This offering involves a securities purchase agreement with a fundamental institutional investor for the acquisition of 1,333,334 common shares or pre-funded warrants, alongside warrants for additional shares. The transaction is projected to generate gross proceeds of approximately $2 million.

The shares are sold alongside warrants, each exercisable at $1.75 with a three-year expiration. D. Boral Capital LLC is facilitating this offering as the exclusive placement agent. The closure is anticipated around May 18, 2026, pending standard conditions.

The shares are being offered under a shelf registration statement made effective by the SEC. Information on the offering will be accessible via a prospectus supplement on the SEC's website.